116 related articles for article (PubMed ID: 11829133)
1. Effect of 7-day exposure to midazolam on electroencephalogram pharmacodynamics in rats: a model to study multiple pharmacokinetic-pharmacodynamic relationships in individual animals.
Laurijssens BE; Greenblatt DJ
J Pharm Pharmacol; 2002 Jan; 54(1):77-86. PubMed ID: 11829133
[TBL] [Abstract][Full Text] [Related]
2. Rate of change of blood concentrations is a major determinant of the pharmacodynamics of midazolam in rats.
Cleton A; Mazee D; Voskuyl RA; Danhof M
Br J Pharmacol; 1999 May; 127(1):227-35. PubMed ID: 10369477
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic-EEG effect relationship of midazolam in aging BN/BiRij rats.
Hovinga S; Stijnen AM; Langemeijer MW; Mandema JW; van Bezooijen CF; Danhof M
Br J Pharmacol; 1992 Sep; 107(1):171-7. PubMed ID: 1422570
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-pharmacodynamic modelling of the EEG effects of midazolam in individual rats: influence of rate and route of administration.
Mandema JW; Tukker E; Danhof M
Br J Pharmacol; 1991 Mar; 102(3):663-8. PubMed ID: 1364836
[TBL] [Abstract][Full Text] [Related]
5. Differences in intrinsic efficacy of benzodiazepines are reflected in their concentration-EEG effect relationship.
Mandema JW; Kuck MT; Danhof M
Br J Pharmacol; 1992 Jan; 105(1):164-70. PubMed ID: 1350744
[TBL] [Abstract][Full Text] [Related]
6. Relevance of arteriovenous concentration differences in pharmacokinetic-pharmacodynamic modeling of midazolam.
Tuk B; Herben VM; Mandema JW; Danhof M
J Pharmacol Exp Ther; 1998 Jan; 284(1):202-7. PubMed ID: 9435179
[TBL] [Abstract][Full Text] [Related]
7. A pilot pharmacokinetic-pharmacodynamic study of benzodiazepine antagonism by flumazenil and aminophylline.
Bonfiglio MF; Fisher-Katz LE; Saltis LM; Traeger SM; Martin BR; Nackes NA; Perkins TA
Pharmacotherapy; 1996; 16(6):1166-72. PubMed ID: 8947991
[TBL] [Abstract][Full Text] [Related]
8. Mechanism-based pharmacodynamic modeling of the interaction of midazolam, bretazenil, and zolpidem with ethanol.
Tuk B; van Gool T; Danhof M
J Pharmacokinet Pharmacodyn; 2002 Jun; 29(3):235-50. PubMed ID: 12449497
[TBL] [Abstract][Full Text] [Related]
9. In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat.
Kotegawa T; Laurijssens BE; Von Moltke LL; Cotreau MM; Perloff MD; Venkatakrishnan K; Warrington JS; Granda BW; Harmatz JS; Greenblatt DJ
J Pharmacol Exp Ther; 2002 Sep; 302(3):1228-37. PubMed ID: 12183684
[TBL] [Abstract][Full Text] [Related]
10. In vivo modeling of the pharmacodynamic interaction between benzodiazepines which differ in intrinsic efficacy.
Mandema JW; Kuck MT; Danhof M
J Pharmacol Exp Ther; 1992 Apr; 261(1):56-61. PubMed ID: 1560385
[TBL] [Abstract][Full Text] [Related]
11. In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil.
Mandema JW; Tukker E; Danhof M
J Pharmacol Exp Ther; 1992 Jan; 260(1):36-44. PubMed ID: 1309878
[TBL] [Abstract][Full Text] [Related]
12. The effect of age on the pharmacokinetics and pharmacodynamics of midazolam.
Albrecht S; Ihmsen H; Hering W; Geisslinger G; Dingemanse J; Schwilden H; Schüttler J
Clin Pharmacol Ther; 1999 Jun; 65(6):630-9. PubMed ID: 10391668
[TBL] [Abstract][Full Text] [Related]
13. Integrated pharmacokinetics and pharmacodynamics of Ro 48-6791, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects.
Dingemanse J; van Gerven JM; Schoemaker RC; Roncari G; Oberyé JJ; van Oostenbruggen MF; Massarella J; Segala P; Zell M; Cohen AF
Br J Clin Pharmacol; 1997 Nov; 44(5):477-86. PubMed ID: 9384465
[TBL] [Abstract][Full Text] [Related]
14. A population analysis of the pharmacokinetics and pharmacodynamics of midazolam in the rat.
Aarons L; Mandema JW; Danhof M
J Pharmacokinet Biopharm; 1991 Oct; 19(5):485-96. PubMed ID: 1783988
[TBL] [Abstract][Full Text] [Related]
15. Quantification of the EEG effect of midazolam by aperiodic analysis in volunteers. Pharmacokinetic/pharmacodynamic modelling.
Breimer LT; Hennis PJ; Burm AG; Danhof M; Bovill JG; Spierdijk J; Vletter AA
Clin Pharmacokinet; 1990 Mar; 18(3):245-53. PubMed ID: 2323155
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and alpha-OH-midazolam.
Tuk B; van Oostenbruggen MF; Herben VM; Mandema JW; Danhof M
J Pharmacol Exp Ther; 1999 May; 289(2):1067-74. PubMed ID: 10215689
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic-pharmacodynamic modeling of electroencephalographic effects of midazolam in eight Chinese men.
Lu JF; Chen G; Xiang BR; An DK
Zhongguo Yao Li Xue Bao; 1994 Sep; 15(5):399-403. PubMed ID: 7717060
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic-pharmacodynamic modeling of the electroencephalographic effects of benzodiazepines. Correlation with receptor binding and anticonvulsant activity.
Mandema JW; Sansom LN; Dios-Vièitez MC; Hollander-Jansen M; Danhof M
J Pharmacol Exp Ther; 1991 Apr; 257(1):472-8. PubMed ID: 1850477
[TBL] [Abstract][Full Text] [Related]
19. Additive effect of midazolam and progesterone on the EEG in rats.
Hoyo-Vadillo C; López-Trujillo E; Venturelli CR
Proc West Pharmacol Soc; 2003; 46():132-3. PubMed ID: 14699909
[No Abstract] [Full Text] [Related]
20. A comparison of the concentration-effect relationships of midazolam for EEG-derived parameters and saccadic peak velocity.
Van Steveninck AL; Mandema JW; Tuk B; Van Dijk JG; Schoemaker HC; Danhof M; Cohen AF
Br J Clin Pharmacol; 1993 Aug; 36(2):109-15. PubMed ID: 8398578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
